歌礼制药-B：歌礼将携ASC30口服片、ASC30注射剂和ASC31与ASC47联合疗法的研究结果亮相2025年肥胖周

Core Insights - The company announced that it will present multiple obesity drug candidates, including ASC30 and the combination therapy of ASC31 and ASC47, at the 2025 ObesityWeek in Atlanta, Georgia [1] - The CEO expressed excitement about the progress of their small molecule and peptide obesity pipeline, highlighting the company's commitment to developing differentiated obesity treatment options [1] Company Developments - The company is actively advancing its obesity treatment pipeline, showcasing its candidates at a significant industry event [1] - The announcement reflects the company's strategic focus on addressing obesity through innovative therapies [1]